Advertisement

CardioVascular and Interventional Radiology

, Volume 42, Issue 10, pp 1475–1482 | Cite as

Toward Transpulmonary Chemoembolization with Degradable Starch Microspheres: Systematic Analysis of Local and Systemic Effects in a Porcine Model

  • A. Barabasch
  • S. von Stillfried
  • C. K. Kuhl
  • A. Heinzel
  • A. Sander
  • P. IsfortEmail author
Laboratory Investigation

Abstract

Purpose

To investigate local and systemic effects of transpulmonary chemoembolization (TPCE) with degradable starch microspheres (DSM) and doxorubicin. The long-term goal is to establish DSM-TPCE as a treatment option for pulmonary malignancies.

Materials and Methods

Nine pigs underwent TPCE of either the right or left lower lobe pulmonary artery (LLPA) and bland embolization (TPE) of the contralateral LLPA. Before the procedures, macroaggregated albumin (MAA) particles were injected into both LLPAs, to exclude systemic shunting. Pulmonary arterial pressure, heart rate and oxygenation were recorded immediately before and at 1, 3, 5 and 10 min after treatment.

To investigate possible nontarget embolization, animals underwent cerebral MRI (cMRI). We killed the animals after a contrast-enhanced chest computed tomography (CT) and performed a pathologic examination at 12 h (3), 24 h (3) and 72 h (3) after treatment.

Results

All experiments were technically successful. Mean injected DSM dose until stasis was similar in TPCE and TPE (4.3 ± 1.4 vs. 4.0 ± 1.4 mL). Pulmonary arterial pressure increased significantly 3 min after treatment (TPE: 17 ± 5 vs. 27 ± 7 mmHg; TPCE: 22 ± 6 vs. 36 ± 8 mmHg). No significant changes in heart rate or peripheral oxygenation levels occurred. We observed no evidence of structural lung damage or permanent perfusion disruption on CT. MAA test injection and cMRI revealed no shunting or nontarget embolization. The pathologic assessment revealed nonspecific local inflammation of the lung parenchyma.

Conclusion

In this large-animal model, TPCE and TPE appear feasible and safe. We observed a mild increase in pulmonary arterial pressure. Nontarget embolization did not occur. TPCE, as well as TPE, did not cause structural damage to the normal lung parenchyma.

Notes

Acknowledgments

Part of this work was presented previously at CIRSE 2017 in Copenhagen (Cardiovasc Intervent Radiol (2017) 40(Suppl 2): 25. https://doi.org/10.1007/s00270-017-1725-y).

Funding

This study was funded by Pharmacept®. Design of the study and collection, analysis and interpretation of data as well as writing of the manuscript were solely performed by the above-mentioned authors.

Compliance with Ethical Standards

Conflicts of interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.

Informed Consent

For this type of study, informed consent is not required.

References

  1. 1.
    Siegel RL, Miller KD. Jemal A (2016) Cancer statistics. CA Cancer J Clin. 2016;66(1):7–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Weiss W, Boucot KR, Cooper DA. The Philadelphia pulmonary neoplasm research project. Survival factors in bronchogenic carcinoma. JAMA. 1971;216(13):2119–233.PubMedGoogle Scholar
  3. 3.
    Schneider P, Kampfer S, Loddenkemper C, Foitzik T, Buhr HJ. Chemoembolization of the lung improves tumor control in a rat model. Clin Cancer Res. 2002;8(7):2463–8.PubMedGoogle Scholar
  4. 4.
    Schneider P, Foitzik T, Pohlen U, Golder W, Buhr HJ. Temporary unilateral microembolization of the lung-a new approach to regional chemotherapy for pulmonary metastases. J Surg Res. 2002;107(2):159–66.CrossRefPubMedGoogle Scholar
  5. 5.
    Pereira PL, Masala S, Cardiovascular, Interventional Radiological Society of E. Standards of practice: guidelines for thermal ablation of primary and secondary lung tumors. Cardiovasc Interv Radiol. 2012;35(2):247–54.CrossRefGoogle Scholar
  6. 6.
    Vogl TJ, Shafinaderi M, Zangos S, Lindemayr S, Vatankhah K. Regional chemotherapy of the lung: transpulmonary chemoembolization in malignant lung tumors. Semin Intervent Radiol. 2013;30(2):176–84.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Pages PB, Facy O, Mordant P, et al. Isolated lung perfusion as an adjuvant treatment of colorectal cancer lung metastases: a preclinical study in a pig model. PLoS ONE. 2013;8(3):e59485.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Cypel M, Keshavjee S. Novel Technologies for Isolated Lung Perfusion: Beyond Lung Transplant. Thorac Surg Clin. 2016;26(2):139–45.CrossRefPubMedGoogle Scholar
  9. 9.
    Vogl TJ, Mekkawy AIA, Thabet DB, et al. Transvenous pulmonary chemoembolization (TPCE) for palliative or neoadjuvant treatment of lung metastases. Eur Radiol. 2019;29(4):1939–49.CrossRefPubMedGoogle Scholar
  10. 10.
    Pohlen U, Rieger H, Meyer BT, et al. Chemoembolization of lung metastases–pharmacokinetic behavior of carboplatin in a rat model. Anticancer Res. 2007;27(2):809–15.PubMedGoogle Scholar
  11. 11.
    Pohlen U, Rieger H, Albrecht T, Loddenkemper C, Buhr HJ, Schneider P (2007) Chemoembolization with carboplatin of the lung. Feasibility and toxicity in a pig model. Anticancer Res 27(3B):1503–1508PubMedGoogle Scholar
  12. 12.
    Vogl TJ, Wetter A, Lindemayr S, Zangos S. Treatment of unresectable lung metastases with transpulmonary chemoembolization: preliminary experience. Radiology. 2005;234(3):917–22.CrossRefPubMedGoogle Scholar
  13. 13.
    Vogl TJ, Lehnert T, Zangos S, et al. Transpulmonary chemoembolization (TPCE) as a treatment for unresectable lung metastases. Eur Radiol. 2008;18(11):2449–555.CrossRefPubMedGoogle Scholar
  14. 14.
    Kume N, Suga K, Uchisako H, Matsui M, Shimizu K, Matsunaga N. Abnormal extrapulmonary accumulation of 99mTc-MAA during lung perfusion scanning. Ann Nucl Med. 1995;9(4):179–84.CrossRefPubMedGoogle Scholar
  15. 15.
    Brown KT, Do RK, Gonen M, et al. Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. J Clin Oncol. 2016;34(17):2046–53.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Gibson NM, Greufe SE, Hydock DS, Hayward R. Doxorubicin-induced vascular dysfunction and its attenuation by exercise preconditioning. J Cardiovasc Pharmacol. 2013;62(4):355–60.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2019

Authors and Affiliations

  1. 1.Department of Diagnostic and Interventional RadiologyRWTH Aachen University HospitalAachenGermany
  2. 2.Institute of PathologyRWTH Aachen University HospitalAachenGermany
  3. 3.Department of Nuclear MedicineRWTH Aachen University HospitalAachenGermany

Personalised recommendations